Chan S H, Chew T S, Goh E H, Simons M J, Shanmugaratnam K
Int J Cancer. 1976 Aug 15;18(2):139-44. doi: 10.1002/ijc.2910180202.
General cell-mediated immune (CMI) functions in NPC patients were investigated by the in vivo Mantoux and in vitro lymphocyte response to PHA assays. Thirty-eight (50%) of 76 untreated NPC patients were hyporesponsive in the Mantoux assay compared to 27 (25%) of 110 control patients. Forty-three (65.2%) of 66 untreated NPC patients also showed lymphocyte hyporesponsiveness to PHA compared to 15 (15.5%) of 97 control patients. Combined deficiencies were observed in 35 (42.2%) of 83 NPC patients compared to only 2 (3.3%) of 61 control patients. No difference in the frequency of immunodeficiency was observed between "early" and "late" disease patients. CMI functions of treated "remission" NPC patients were found to be impaired to the same extent as those of untreated NPC patients.
通过体内结核菌素试验和体外淋巴细胞对PHA的反应试验，对鼻咽癌（NPC）患者的一般细胞介导免疫（CMI）功能进行了研究。76例未经治疗的NPC患者中有38例（50%）在结核菌素试验中反应低下，而110例对照患者中有27例（25%）反应低下。66例未经治疗的NPC患者中有43例（65.2%）对PHA的淋巴细胞反应也低下，而97例对照患者中有15例（15.5%）反应低下。83例NPC患者中有35例（42.2%）存在联合缺陷，而61例对照患者中只有2例（3.3%）存在联合缺陷。“早期”和“晚期”疾病患者的免疫缺陷频率没有差异。发现接受治疗处于“缓解期”的NPC患者的CMI功能与未经治疗的NPC患者受损程度相同。
